Lv2
136 积分 2023-01-11 加入
Synthetic lethality and cancer
2天前
已完结
The DNA damage response: putting checkpoints in perspective
3天前
已完结
CELL CYCLE AND CELL-CYCLE CHECKPOINTS
3天前
已完结
Chapter 17 - Targeting the Cell Cycle to Kill Cancer Cells
3天前
已完结
Chapter Eleven - Anti-cancer drug molecules targeting cancer cell cycle and proliferation
3天前
已完结
Resistance to BRAF-targeted therapy in melanoma
4天前
已关闭
4 - Control of the Cell Cycle
4天前
已完结
The New Frontier: Merging Molecular Glue Degrader and Antibody-Drug Conjugate Modalities To Overcome Strategic Challenges
9天前
已完结
Targeting cancer with small-molecule pan-KRAS degraders
11天前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
12天前
已完结
皖公网安备34019202002308
